Top Vertex exec to retire after more than 12 years with company
Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue growth over the past decade.
Vertex's Revenue Surges but EPS Slips
The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.
Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...